|
1
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burnett A, Wetzler M and Löwenberg B:
Therapeutic advances in acute myeloid leukemia. J Clin Oncol.
29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Kouchkovsky I and Abdul-Hay M: Acute
myeloid leukemia: A comprehensive review and 2016 update. Blood
Cancer J. 6:e4412016. View Article : Google Scholar
|
|
4
|
Roboz GJ: Current treatment of acute
myeloid leukemia. Curr Opin Oncol. 24:711–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bullinger L, Döhner K and Döhner H:
Genomics of acute myeloid leukemia diagnosis and pathways. J Clin
Oncol. 35:934–946. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ernst C and Morton CC: Identification and
function of long non-coding RNA. Front Cell Neurosci. 7:1682013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li CH and Chen Y: Targeting long
non-coding RNAs in cancers: Progress and prospects. Int J Biochem
Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Cheng Z, Pang Y, Cui L, Qian T,
Quan L, Zhao H, Shi J, Ke X and Fu L: Role of microRNAs, circRNAs
and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol.
12:512019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu C, Cui H, Li H, Wu Y, An H and Guo C:
Long non-coding RNA ZEB2-AS1 expression is associated with disease
progression and predicts outcome in gastric cancer patients. J
BUON. 24:663–671. 2019.PubMed/NCBI
|
|
10
|
Guo Y, Hu Y, Hu M, He J and Li B: Long
non-coding RNA ZEB2-AS1 promotes proliferation and inhibits
apoptosis in human lung cancer cells. Oncol Lett. 15:5220–5226.
2018.PubMed/NCBI
|
|
11
|
Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y
and Zhang G: LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth
and invasion through regulating the miR-204/HMGB1 axis. Int J Biol
Macromol. 116:545–551. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi X, Li J, Ma L, Wen L, Wang Q, Yao H,
Ruan C, Wu D, Zhang X and Chen S: Overexpression of ZEB2-AS1 lncRNA
is associated with poor clinical outcomes in acute myeloid
leukemia. Oncol Lett. 17:4935–4947. 2019.PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kavitha N, Vijayarathna S, Jothy SL, Oon
CE, Chen Y, Kanwar JR and Sasidharan S: MicroRNAs: Biogenesis,
roles for carcinogenesis and as potential biomarkers for cancer
diagnosis and prognosis. Asian Pac J Cancer Prev. 15:7489–7497.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang J, Yuan Y, Yang X, Hong Z and Yang L:
Decreased expression of microRNA-122 is associated with an
unfavorable prognosis in childhood acute myeloid leukemia and
function analysis indicates a therapeutic potential. Pathol Res
Pract. 213:1166–1172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang TJ, Qian Z, Wen XM, Zhou JD, Li XX,
Xu ZJ, Ma JC, Zhang ZH, Lin J and Qian J: Lower expression of bone
marrow miR-122 is an independent risk factor for overall survival
in cytogenetically normal acute myeloid leukemia. Pathol Res Pract.
214:896–901. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colicino EG and Hehnly H: Regulating a key
mitotic regulator, polo-like kinase 1 (PLK1). Cytoskeleton
(Hoboken). 75:481–494. 2018. View
Article : Google Scholar
|
|
19
|
Weng Ng WT, Shin JS, Roberts TL, Wang B
and Lee CS: Molecular interactions of polo-like kinase 1 in human
cancers. J Clin Pathol. 69:557–562. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brandwein JM: Targeting polo-like kinase 1
in acute myeloid leukemia. Ther Adv Hematol. 6:80–87. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA
language. Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Khwaja A, Bjorkholm M, Gale RE, Levine RL,
Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A,
Cornelissen JJ, et al: Acute myeloid leukaemia. Nat Rev Dis
Primers. 2:160102016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mardis ER, Ding L, Dooling DJ, Larson DE,
McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath
SD, et al: Recurring mutations found by sequencing an acute myeloid
leukemia genome. N Engl J Med. 361:1058–1066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Young AL, Tong RS, Birmann BM and Druley
TE: Clonal haematopoiesis and risk of acute myeloid leukemia.
Haematologica. 104:2410–2417. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rathinasamy B and Velmurugan BK: Role of
lncRNAs in the cancer development and progression and their
regulation by various phytochemicals. Biomed Pharmacother.
102:242–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang G, Li H, Sun R, Li P, Yang Z, Liu Y,
Wang Z, Yang Y and Yin C: Long non-coding RNA ZEB2-AS1 promotes the
proliferation, metastasis and epithelial mesenchymal transition in
triple-negative breast cancer by epigenetically activating ZEB2. J
Cell Mol Med. 23:3271–3279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu X, Yan T, Wang Z, Wu X, Cao G and Zhang
C: LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and
inhibits apoptosis by regulating miR-27b. Biomed Pharmacother.
96:299–304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duan Y, Dong Y, Dang R, Hu Z, Yang Y, Hu Y
and Cheng J: MiR-122 inhibits epithelial mesenchymal transition by
regulating P4HA1 in ovarian cancer cells. Cell Biol Int.
42:1564–1574. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu YH, Liu JL, Wang Z, Zhu XH, Chen XB
and Wang MQ: MiR-122-5p suppresses cell proliferation, migration
and invasion by targeting SATB1 in nasopharyngeal carcinoma. Eur
Rev Med Pharmacol Sci. 23:622–629. 2019.PubMed/NCBI
|
|
31
|
Zhang L, Wang Y, Sun J, Ma H and Guo C:
LINC00205 promotes proliferation, migration and invasion of HCC
cells by targeting miR-122-5p. Pathol Res Pract. 215:1525152019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Z, Liu G, Zhang M, Zhang Z, Jia Y, Peng
L, Zhu Y, Hu J, Huang R and Sun X: MiR-122-5p inhibits the
proliferation, invasion and growth of bile duct carcinoma cells by
targeting ALDOA. Cell Physiol Biochem. 48:2596–2606. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Ann Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Z, Sun Q and Wang X: PLK1, a potential
target for cancer therapy. Transl Oncol. 10:22–32. 2017. View Article : Google Scholar
|
|
35
|
Dang SC, Fan YY, Cui L, Chen JX, Qu JG and
Gu M: PLK1 as a potential prognostic marker of gastric cancer
through MEK-ERK pathway on PDTX models. Onco Targets Ther.
11:6239–6247. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z,
Chen J, Liu Z, Lei Z, Zhang HT, et al: MiR-296-5p suppresses cell
viability by directly targeting PLK1 in non-small cell lung cancer.
Oncol Rep. 35:497–503. 2016. View Article : Google Scholar
|
|
37
|
Li J, Wang R, Schweickert PG, Karki A,
Yang Y, Kong Y, Ahmad N, Konieczny SF and Liu X: Plk1 inhibition
enhances the efficacy of gemcitabine in human pancreatic cancer.
Cell Cycle. 15:711–719. 2016. View Article : Google Scholar : PubMed/NCBI
|
